Inari Medical, now part of Stryker, launches the all-new InThrill庐 Thrombectomy System, designed to address arteriovenous access and small vessel thrombus cases
Inari Medical, a division of Stryker (NYSE:SYK), has launched the next-generation InThrill庐 Thrombectomy System, marking a significant advancement in small vessel and arteriovenous (AV) access thrombectomy procedures.
The new 8 French over-the-wire system features enhanced capabilities including increased radial force for better luminal wall apposition, offset single open mouth for optimized clot capture, internal struts for even clot distribution, and improved ergonomics. The first commercial case was successfully performed on May 19, 2025, at UPMC health care system by Dr. Joshua Pinter and Dr. Anish Ghodadra.
Inari Medical, divisione di Stryker (NYSE:SYK), ha lanciato il nuovo InThrill庐 Thrombectomy System di ultima generazione, rappresentando un importante progresso nelle procedure di trombectomia per piccoli vasi e accessi artero-venosi (AV).
Il nuovo sistema over-the-wire da 8 French presenta capacit脿 migliorate, tra cui una maggiore forza radiale per un migliore adattamento alla parete del lume, una bocca singola aperta sfalsata per un鈥檕ttimale cattura del coagulo, supporti interni per una distribuzione uniforme del coagulo e un鈥檈rgonomia perfezionata. Il primo caso commerciale 猫 stato eseguito con successo il 19 maggio 2025 presso il sistema sanitario UPMC dai dottori Joshua Pinter e Anish Ghodadra.
Inari Medical, una divisi贸n de Stryker (NYSE:SYK), ha lanzado el InThrill庐 Thrombectomy System de pr贸xima generaci贸n, marcando un avance significativo en los procedimientos de trombectom铆a para vasos peque帽os y accesos arteriovenosos (AV).
El nuevo sistema over-the-wire de 8 French cuenta con capacidades mejoradas, incluyendo una mayor fuerza radial para una mejor aposici贸n a la pared luminal, boca 煤nica abierta desplazada para una captura 贸ptima del co谩gulo, soportes internos para una distribuci贸n uniforme del co谩gulo y una ergonom铆a mejorada. El primer caso comercial se realiz贸 con 茅xito el 19 de mayo de 2025 en el sistema de salud UPMC por los doctores Joshua Pinter y Anish Ghodadra.
Inari Medical电� Stryker (NYSE:SYK)鞚� 頃� 攵�靹滊靹�, 靻岉槇甏� 氚� 霃欖爼毵�(AV) 鞝戧芳 順堨爠鞝滉卑靾� 攵勳暭鞐愳劀 須嶊赴鞝侅澑 氚滌爠鞚� 鞚措， 彀劯雽� InThrill庐 Thrombectomy System鞚� 於滌嫓頄堨姷雼堧嫟.
靸堧鞖� 8 French 鞓る矂雿旍檧鞚挫柎 鞁滌姢韰滌潃 雿� 雮橃潃 順堦磤 雮措步 氚�彀╈潉 鞙勴暅 頄レ儊霅� 氚╈偓霠�, 斓滌爜鞚� 順堨爠 韽殟鞚� 鞙勴暅 鞓ろ攧靺� 雼澕 臧滉惮攵�, 順堨爠 攵勴彫毳� 攴犾澕頃橁矊 頃樀鐢 雮措秬 歆�歆�雽�, 攴鸽Μ瓿� 臧滌劆霅� 鞚胳泊瓿淀暀鞝� 靹り硠毳� 韸轨鞙茧 頃╇媹雼�. 觳� 靸侅梾鞝� 鞁滌垹鞚� 2025雲� 5鞗� 19鞚� UPMC 鞚橂 鞁滌姢韰滌棎靹� Joshua Pinter 氚曥偓鞕� Anish Ghodadra 氚曥偓鞐� 鞚橅暣 靹标车鞝侅溂搿� 靾橅枆霅橃棃鞀惦媹雼�.
Inari Medical, une division de Stryker (NYSE:SYK), a lanc茅 le syst猫me de thrombectomie de nouvelle g茅n茅ration InThrill庐 Thrombectomy System, marquant une avanc茅e significative dans les proc茅dures de thrombectomie pour les petits vaisseaux et les acc猫s art茅rioveineux (AV).
Le nouveau syst猫me over-the-wire de 8 French offre des capacit茅s am茅lior茅es, notamment une force radiale accrue pour une meilleure apposition 脿 la paroi du lumen, une ouverture simple d茅cal茅e pour une capture optimale du caillot, des renforts internes pour une distribution uniforme du caillot, et une ergonomie am茅lior茅e. Le premier cas commercial a 茅t茅 r茅alis茅 avec succ猫s le 19 mai 2025 au sein du syst猫me de sant茅 UPMC par le Dr Joshua Pinter et le Dr Anish Ghodadra.
Inari Medical, eine Abteilung von Stryker (NYSE:SYK), hat das n盲chste Generation InThrill庐 Thrombectomy System vorgestellt, das einen bedeutenden Fortschritt bei Thrombektomie-Verfahren an kleinen Gef盲脽en und arterioven枚sen (AV) Zug盲ngen darstellt.
Das neue 8 French Over-the-Wire-System verf眉gt 眉ber verbesserte Funktionen, darunter eine erh枚hte radiale Kraft f眉r eine bessere Wandanschmiegung, eine versetzte einzelne offene 脰ffnung f眉r optimiertes Thrombusfangen, interne Streben f眉r eine gleichm盲脽ige Thrombusverteilung und verbesserte Ergonomie. Der erste kommerzielle Eingriff wurde erfolgreich am 19. Mai 2025 im UPMC-Gesundheitssystem von Dr. Joshua Pinter und Dr. Anish Ghodadra durchgef眉hrt.
- First and only purpose-built small vessel and AV access thrombectomy system for full luminal clot removal
- Enhanced features including increased radial force and improved clot capture capabilities
- Successfully completed first commercial case with positive physician feedback
- None.
Insights
Stryker's new InThrill device strengthens position in thrombectomy market with improved small vessel capabilities.
The second-generation InThrill Thrombectomy System marks a significant advancement in Stryker's vascular intervention portfolio following its Inari Medical acquisition. This 8 French over-the-wire system addresses a specific clinical need in the thrombectomy market - small vessel and arteriovenous access clot removal - with several technical improvements over the previous generation.
The system's design enhancements are clinically meaningful: increased radial force improves wall apposition for better clot engagement; the offset single open mouth optimizes clot capture; internal struts ensure even clot distribution; and ergonomic backend improvements streamline the user experience. These features collectively address physician pain points in challenging thrombectomy cases.
Initial physician feedback from UPMC suggests strong clinical performance, with Dr. Pinter noting more effective and consistent thrombectomies. Dr. Ghodadra's comment about a "changed paradigm of treatment" suggests potential for market share gains in the AV access segment.
This product launch demonstrates Stryker's continued integration of Inari's technology platform and extends the company's reach in the thrombectomy market. By targeting specific vascular intervention niches with purpose-built tools rather than repurposing existing technology, Stryker is employing a differentiation strategy that could strengthen its competitive position against rivals like Boston Scientific, Medtronic, and Penumbra in the thrombectomy space.
The second generation InThrill Thrombectomy System is an 8 French over-the-wire system comprising the InThrill thrombectomy catheter and the InThrill sheath. InThrill is built upon a familiar platform, optimized to become the standard for AV access and small vessel thrombectomy. Offering unmatched efficiency and clot removal, InThrill has distinctive features which include:
- Increased radial force聽for improved luminal wall apposition for optimized clot removal
- Offset single open mouth to optimize clot capture and removal
- Internal struts聽for even clot distribution within the element
- Redesigned backend聽to streamline ergonomics and improve the user experience.
On May 19, 2025, Dr. Joshua Pinter and Dr. Anish Ghodadra of the UPMC health care system performed the first commercial case using the new InThrill Thrombectomy System. "The next generation of InThrill has made our thrombectomies more effective and consistent than ever," said Dr. Pinter. "Inari's dedication to building a small vessel tool has changed our paradigm of treatment for AV access thrombectomy," added Dr. Ghodadra.
"The launch of the next-generation InThrill Thrombectomy System reflects our deep commitment to solving real-world challenges in vascular care," said Tim Lanier, president, Inari Division. "This latest innovation delivers new tools and enriches our work with physicians in the vascular space."
For more information, visit
About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at聽.
On February 19, 2025, Stryker acquired Inari Medical, a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases.
Media contact:
Sacha Ricarte
Director, Communications - Inari
[email protected]
Drs. Anish Ghodadra and Joshua Pinter are not paid consultants of Inari Medical. All views and opinions expressed here are their own and do not represent those of Inari Medical.
Indications for Use:
The InThrill Thrombectomy System is indicated for (1) the non-surgical removal of thrombi and emboli from blood vessels, including arteriovenous fistulae and arteriovenous grafts for dialysis access, and synthetic grafts and (2) injection, infusion, and/or aspiration of contrast media and other fluids into or from a blood vessel/graft. The InThrill Sheath is indicated for use as a conduit for the insertion of endovascular devices into the peripheral vasculature while minimizing blood loss associated with such insertions. The InThrill Thrombectomy System is intended for use in the peripheral vasculature. The InThrill Thrombectomy System is not intended for use in deep vein thrombosis (DVT) treatment.
Review complete Instructions for Use, Indications for Use, Warnings, Precautions, Possible Adverse Effects and Contraindications prior to use of the product.
View original content to download multimedia:
SOURCE Stryker
FAQ
What is the new InThrill庐 Thrombectomy System by Stryker (NYSE:SYK)?
When was the first commercial case of Stryker's new InThrill庐 Thrombectomy System performed?
What are the key features of Stryker's next-generation InThrill庐 Thrombectomy System?
How does the new InThrill庐 Thrombectomy System benefit vascular procedures?
